ClinicalTrials.gg
CompletedNCT06596096Updated Jul 9, 2025

Risk Factors for Beta-lactam Target Non Attainment in Critically Ill Patients BETALACTACRIT

An observational study in Sepsis, sponsored by Centre Hospitalier de Saint-Brieuc. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Centre Hospitalier de Saint-Brieuc · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Sepsis with a site in France — 41 open to participants now, 46 under way, 5 of them phase 3. Sepsis · France.

Enrollment
37th of 97
300 · median 170
Started
2023
with 12 others
Observational
97 of 209
20 open now
Registered
176th of 209
by date

Among the 209 studies in Sepsis with a site in France, this one is the 37th largest by enrollment of the 97 observational ones that give a count, is one of 13 that started in 2023, is one of 97 observational ones, and was the 176th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

41 of the 209 studies in Sepsis with a site in France are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Sepsis with a site in France, or all of them as a file.
02

Study summary

Beta-lactams agents are time-dependent antibiotics. Their bactericidal effects are associated with the time spent above the minimal inhibitory concentration (MIC) of the bacteria. In ICU patients, many pathophysiological changes may occur, which significantly alter beta-lactam pharmacokinetics (increasing in distribution volume, hypoalbuminemia or change in glomerular filtration rate…), leading to antibiotic underexposure, which may explain some treatment failures and risk of emergence of a multi-resistant bacteria.

Many guidelines advocate to reach a fixed target for the steady-state free plasma concentration of beta-lactam between 4 and 8 times of the MIC. However, clinical evidences supporting that septic patients in ICU would benefit from such optimization remain low and contradictory, and use of surrogate MICs based on critical breakpoints instead of actual MICs are significant limitations in the description of beta-lactam exposure among ICU patients with sepsis.

In this study, the investigators aim to indentify profiles of intensive care unit patients which are more likely to be associated with pharmacological failure (\< 4 time the MIC of the bacteria). The investigators also aim to identify association between failure and poor clinical outcome.

Read the detailed description

The duration of patient participation extends from the inclusion visit (D1), to discharge from intensive care; if the participant is still in intensive care at D90, the last visit with data collection will be at D90. The maximum duration of participation in the study will therefore be 3 months.

Taking into account 3 months of set-up, 1 year of recruitment, 3 months of participant follow-up, 3 months of data processing and 3 months of interpretation, 2 years will be sufficient to carry out this project.

03

Conditions studied

  • Sepsis

Browse trials for

Keywords

  • Beta-lactam
  • Underexposure
  • Risk factors
  • Intensive care unit
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients hospitalized in intensive care with sepsis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant over 18 years of age.
  • Hospitalized in intensive care unit.
  • Bacterial infection documented by culture.
  • Treatment with beta-lactam for less than 48 hours.
  • Person not objecting to participation in the study. If the particpant is unable to receive the information, it will be given to a relative and his or her non-opposition will be collected; the patient's non opposition will be sought and collected as soon as his or her condition permits.

Exclusion criteria

Exclusion Criteria:

  • Measurement of MIC of the bacterium in question impossible.
  • Patients allergic to beta-lactam antibiotics.
  • Patients with an estimated hospital stay of less than 3 days.
  • Participants with "complex" infectious sites: central nervous system infection, osteoarticular infection, etc.
  • Patients already included in the present study on the occasion of a previous beta-lactam administration.
  • Adult patients under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
300 participants (actual)
Target follow-up
28 Days
Patient registry
Yes
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Identify proportion of participant with betalactam underexposure in critically ill patients with sepsis and predictive parameters.

    Under-exposure to beta-lactam antibiotics is defined as a plasma concentration below 4x the MIC of the identified bacterium. This concentration will be measured as residual in the case of discontinuous administration, or at equilibrium in the case of continuous administration. This criterion is assessed between 48 and 72 hours after the start of antibiotic therapy. Variables that will be assessed include age (in years), body mass index (in kg/m²), renal clearance (calculated with creatininemia, urinary creatininuria urinary volumeper day expressed in mL/min), SAPSII score (no unit), site of infection, modality of antibiotic administration (intermittent, continuous), time since first antibiotic injection (in hours), body temperature (in °C), SOFA score (no units), blood cell numeration (in cell/mL), coagulation parameters (in % of activity), protidemia (in g/L), lactates level (in mmol/L).

    Time frame: 25 months

Secondary outcomes

  1. Count the number of participants with poor clinical outcome and pharmacological failure (< 4 times the bacterial MIC).

    The secondary objective is to establish the association between under-exposure to betalactam antibiotics in ICU participants and their clinical outcome. Pharmacological failure, defined as \< 4 times the bacterial MIC, will be correlated with poor clinical outcome, up to and including death.

    Time frame: 25 months

07

Study locations

1 site
  • FILLATRE
    Saint-Brieuc, 22000, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Jun 2025, 23 months.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's 23 months is below that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Sep 19, 2024
StartActual
Jun 12, 2023
Primary completionActual
Jun 11, 2025
CompletionActual
Jun 30, 2025
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06596096
Lead sponsor
Centre Hospitalier de Saint-Brieuc
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Jun 12, 2023
Primary completion
Jun 11, 2025
Completion
Jun 30, 2025
Last update
Jul 9, 2025

Study contacts

Pierre FILLATRE
principal investigator · CENTRE HOSPITALIER SAINT-BRIEUC PAIMPOL TREGUIER REANIMATION
Nicolas NESSELER
study chair · CHU RENNES REANIMATION CHIRURGIE THORACIQUE CARDIAQUE ET VASCULAIRE
Yoann LAUNEY
study chair · CHU RENNES REANIMATION CHIRURGICALE
Flora DELAMAIRE
study chair · CHU RENNES REANIMATION MEDICALE
Guillaume RIEUL
study chair · CH BRETAGNE ATLANTIQUE REANIMATION
Pierre BOUJU
study chair · ch bretagne sud atlantique REANIMATION
Aurélien FREROU
principal investigator · CH ST MALO REANIMATION

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion